145 related articles for article (PubMed ID: 37423059)
1. Cerebrospinal fluid as a liquid biopsy for molecular characterization of brain metastasis in patients with non-small cell lung cancer.
Tsakonas G; Tadigotla V; Chakrabortty SK; Stragliotto G; Chan D; Lewensohn R; Yu W; Skog JK; Hydbring P; Ekman S
Lung Cancer; 2023 Aug; 182():107292. PubMed ID: 37423059
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC.
Wu J; Liu Z; Huang T; Wang Y; Song MM; Song T; Long G; Zhang X; Li X; Zhang L
Mol Oncol; 2023 May; 17(5):810-824. PubMed ID: 36495130
[TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
4. Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.
Zheng MM; Li YS; Jiang BY; Tu HY; Tang WF; Yang JJ; Zhang XC; Ye JY; Yan HH; Su J; Zhou Q; Zhong WZ; Yang XN; Guo WB; Chuai S; Zhang Z; Chen HJ; Wang Z; Liu C; Wu YL
J Thorac Oncol; 2019 May; 14(5):924-932. PubMed ID: 30659989
[TBL] [Abstract][Full Text] [Related]
5. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid ctDNA testing shows an advantage over plasma ctDNA testing in advanced non-small cell lung cancer patients with brain metastases.
Liu X; Mei F; Fang M; Jia Y; Zhou Y; Li C; Tian P; Lu C; Li G
Front Oncol; 2023; 13():1322635. PubMed ID: 38269023
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal Metastases.
Song Y; Liu P; Huang Y; Guan Y; Han X; Shi Y
Curr Cancer Drug Targets; 2019; 19(8):666-673. PubMed ID: 30332963
[TBL] [Abstract][Full Text] [Related]
8. Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a prospective cohort study.
Li M; Hou X; Zheng L; Ma Y; Li D; Lv Y; Chen J; Zheng W; Shao Y; Mou Y; Chen L
ESMO Open; 2022 Feb; 7(1):100305. PubMed ID: 34922300
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
[TBL] [Abstract][Full Text] [Related]
10. [Different Gene Mutation Spectrum of the Paired CSF and Plasma Samples in Lung Adenocarcinoma with Leptomeningeal Metastases: the Liquid Biopsy Based on Circulating Tumor DNA].
Li H; Xie Y; Lin Y; Yu T; Yin Z
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):646-654. PubMed ID: 32838487
[TBL] [Abstract][Full Text] [Related]
11. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
[TBL] [Abstract][Full Text] [Related]
12. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon
Ma C; Zhang J; Tang D; Ye X; Li J; Mu N; Li Z; Liu R; Xiang L; Huang C; Jiang R
Front Oncol; 2020; 10():224. PubMed ID: 32195178
[No Abstract] [Full Text] [Related]
14. Unique genomic profiles obtained from cerebrospinal fluid cell-free DNA of non-small cell lung cancer patients with leptomeningeal metastases.
Ying S; Ke H; Ding Y; Liu Y; Tang X; Yang D; Li M; Liu J; Yu B; Xiang J; Mao X; Han-Zhang H; Hu W; Chen L
Cancer Biol Ther; 2019; 20(4):562-570. PubMed ID: 30395779
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution.
Yang H; Wen L; Zhao C; Chen J; Zhou Z; Zhou C; Cai L; Zhou C
Heliyon; 2022 Dec; 8(12):e12374. PubMed ID: 36643302
[TBL] [Abstract][Full Text] [Related]
16. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
Zhao J; Ye X; Xu Y; Chen M; Zhong W; Sun Y; Yang Z; Zhu G; Gu Y; Wang M
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1305-1310. PubMed ID: 27770237
[TBL] [Abstract][Full Text] [Related]
18. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
[TBL] [Abstract][Full Text] [Related]
19. Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Krug AK; Enderle D; Karlovich C; Priewasser T; Bentink S; Spiel A; Brinkmann K; Emenegger J; Grimm DG; Castellanos-Rizaldos E; Goldman JW; Sequist LV; Soria JC; Camidge DR; Gadgeel SM; Wakelee HA; Raponi M; Noerholm M; Skog J
Ann Oncol; 2018 Mar; 29(3):700-706. PubMed ID: 29216356
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Value of Cerebrospinal Fluid ctDNA in Patients
with Non-small Cell Lung Cancer Meningeal Metastasis].
Zhang K; Dai Z; Liu S; Li D; Yang D; Cui S
Zhongguo Fei Ai Za Zhi; 2020 Dec; 23(12):1039-1048. PubMed ID: 33357310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]